Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Inclusion Criteria: * Male or Female aged ≥18 years old; * Histologically or cytopathologically confirmed non-small cell lung cancer (NSCLC) ; * According to RANO-BM, the subject has at least 1 intracranial measurable lesion; * Tumor tissue samples or blood samples are confirmed to be EGFR mutations; * ECOG PS 0-1; * Life expectancy \>12 weeks; * No prior systemic antitumor therapy for metastatic NSCLC Exclusion Criteria: * Patients without lung adenocarcinoma, including lung squamous cell carcinoma or mixed histological type, etc; * Expected to receive other anti-tumor therapy other than the investigational product during the study; * Having previously received systematic anti-tumor therapy * Having received the following therapies: (1) Having been irradiated for \> 30% bone marrow or a large area within 4 weeks prior to the first dose of investigational product; (2) Having received major surgery within 4 weeks prior to the first dose of investigational product or plan to receive major surgery during the study with exception of the surgical procedures to establish vascular access, biopsy through mediastinoscopy or thoracoscopy; (3) Use of a potent CYP3A4 inhibitor within 7 days prior to the first dose of investigational product or a potent CYP3A4 inducer within 21 days prior to the first dose of investigational product; use of the traditional Chinese medicine or traditional Chinese medicine preparation with tumor indication, or traditional Chinese medicine or traditional …